All In Biotech

Drug Trial Radar · NCT07136545

A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)

Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Aug 13, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Taipei Veterans General Hospital, TaiwanGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
FBD Biologics Limited; National Taiwan University Hospital; Chang Gung Memorial Hospital
First posted
Aug 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a non-randomized, open-label, dose-escalation and dose-expansion phase I/II clinical study to evaluate the safety, tolerability, and efficacy of HCB101 in combination with pembrolizumab in patients with platinum-refractory recurrent/metastatic HNSCC. The trial consists of two phases: the dose-escalation phase (I) and the dose-expansion phase (II). Subjects will receive a weekly single dose of HCB101 IV infusion over 60 (±10) minutes on Days 1, 8, and 15 in each 21-day cycle in combination with pembrolizumab (200 mg IV day 1; given every 21 days) until unacceptable AE(s), radiographic or clinically documented disease progression, withdrawal of consent, loss to follow-up, death, or termination of the study whichever occurs first.

Conditions

  • HNSCC

Interventions

  • HCB101Drug

    QW

  • PembrolizumabDrug

    200 mg IV on Day 1, cycled every 21 days;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with MTD of HCB101 in combination with pembrolizumabTime frame: 2 Years
  2. Overall Rate Response (ORR)Time frame: 2 Years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Chang-Gung Memorial Hospital(Lin-Kou)

    Taoyuan, Guishan District, Taiwan · Recruiting

  • National Taiwan University Hospital

    Taipei, Taipei City, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taipei City, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.